Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma Statistics

Total Valuation

CBIO has a market cap or net worth of $616.40 million. The enterprise value is $428.78 million.

Market Cap	616.40M
Enterprise Value	428.78M

Important Dates

The last earnings date was Wednesday, April 29, 2026, after market close.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	n/a

Share Statistics

CBIO has 33.23 million shares outstanding.

Current Share Class	27.57M
Shares Outstanding	33.23M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+44.35%
Owned by Insiders (%)	4.68%
Owned by Institutions (%)	50.82%
Float	14.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	51.87
Forward PS	n/a
PB Ratio	3.43
P/TBV Ratio	3.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	36.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.78, with a Debt / Equity ratio of 0.01.

Current Ratio	13.78
Quick Ratio	13.33
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-152.04

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-88.21%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$270,068
Profits Per Employee	-$3.68M
Employee Count	44
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, CBIO has paid $2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	17.66
200-Day Moving Average	13.69
Relative Strength Index (RSI)	46.75
Average Volume (20 Days)	341,321

Short Selling Information

The latest short interest is 2.40 million, so 7.21% of the outstanding shares have been sold short.

Short Interest	2.40M
Short Previous Month	2.23M
Short % of Shares Out	7.21%
Short % of Float	16.41%
Short Ratio (days to cover)	9.00

Income Statement

In the last 12 months, CBIO had revenue of $11.88 million and -$162.08 million in losses. Loss per share was -$8.05.

Revenue	11.88M
Gross Profit	11.88M
Operating Income	-163.14M
Pretax Income	-160.08M
Net Income	-162.08M
EBITDA	n/a
EBIT	-163.14M
Loss Per Share	-$8.05

Balance Sheet

The company has $189.16 million in cash and $1.54 million in debt, with a net cash position of $187.62 million or $5.65 per share.

Cash & Cash Equivalents	189.16M
Total Debt	1.54M
Net Cash	187.62M
Net Cash Per Share	$5.65
Equity (Book Value)	183.85M
Book Value Per Share	5.41
Working Capital	181.37M

Cash Flow

In the last 12 months, operating cash flow was -$69.62 million and capital expenditures -$1.07 million, giving a free cash flow of -$70.68 million.

Operating Cash Flow	-69.62M
Capital Expenditures	-1.07M
Depreciation & Amortization	148,000
Net Borrowing	n/a
Free Cash Flow	-70.68M
FCF Per Share	-$2.13

Margins

Gross Margin	100.00%
Operating Margin	-1,372.86%
Pretax Margin	-1,347.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-26.29%
FCF Yield	-11.47%

Analyst Forecast

The average price target for CBIO is $29.43, which is 58.65% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$29.43
Price Target Difference	58.65%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	80.58%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CBIO has an Altman Z-Score of 7.59 and a Piotroski F-Score of 1.

Altman Z-Score	7.59
Piotroski F-Score	1